First Regular Session - 2015

IN THE HOUSE OF REPRESENTATIVES

HOUSE BILL NO. 235

BY HEALTH AND WELFARE COMMITTEE

7 17 7 7 7

,	AN ACI
2	RELATING TO HEALTH INSURANCE; AMENDING CHAPTER 18, TITLE 41, IDAHO CODE,
3	BY THE ADDITION OF A NEW SECTION 41-1852, IDAHO CODE, TO ESTABLISH RE-
4	QUIREMENTS FOR HEALTH INSURANCE POLICIES COVERING CERTAIN TYPES OF
5	CHEMOTHERA PY

Be It Enacted by the Legislature of the State of Idaho:

SECTION 1. That Chapter 18, Title 41, Idaho Code, be, and the same is hereby amended by the addition thereto of a <u>NEW SECTION</u>, to be known and designated as Section 41-1852, Idaho Code, and to read as follows:

- 41-1852. CANCER TREATMENT PARITY. (1) Except as provided in subsection (2) of this section, any health insurance policy that covers prescribed oral chemotherapy and intravenously administered chemotherapy shall ensure that the cost sharing applied to the covered oral chemotherapy is no more restrictive than the cost sharing applied to the covered intravenously administered chemotherapy.
- (2) A health insurance policy may apply more restrictive cost sharing to oral chemotherapy only if such cost sharing does not exceed one hundred fifty dollars (\$150) per prescription.
- (3) A health insurance carrier shall not increase the cost sharing for intravenously administered chemotherapy for the purpose of achieving compliance with this section.
 - (4) As used in this section:
 - (a) "Cost sharing" means the maximum out-of-pocket costs for the insured as defined by a health insurance policy.
 - (b) "Intravenously administered chemotherapy" means a physician-prescribed cancer treatment that is used to kill or slow the growth of cancer cells and that is administered through injection directly into the patient's circulatory system by an authorized health care professional in a hospital, medical office or other clinical setting.
 - (c) "Oral chemotherapy" means a physician-prescribed cancer treatment approved by the federal food and drug administration that is used to kill or slow the growth of cancer cells and that is taken orally in the form of a tablet or capsule, which may be administered in a hospital, medical office or other clinical setting or may be delivered to the patient for self-administration under the direction or supervision of a physician outside of a hospital, medical office or other clinical setting.
- (5) This section applies to health insurance policies renewed or entered into on or after July 1, 2015.